Deep sequencing of breakthrough infections from the AMP trials shows that prophylactic VRC01 selected for low-frequency HIV ...
A randomized phase 2a trial found the SARS-CoV-2 monoclonal antibody AER002 safe but ineffective for Long COVID overall, ...
VMS063 is a novel, potential first- and best-in-class monoclonal antibody investigational candidate discovered by Invivyd The U.S. is experiencing a record-breaking number of measles cases in 2026, ...
The initiation of the Phase 1/2a clinical trial will represent a key milestone in advancing a first-in-class HMGB1-targeted immunomodulatory antibody for patients with frontotemporal lobar ...
Therapeutic antibodies have already revolutionized the management of many cancers, as well as autoimmune and inflammatory diseases. Their great strength? Their ability to pinpoint a biological target ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results